CliniMACS CD34^-selected cells to support multiple cycles of high-dose therapy

By Prince HM   Wall D   Rischin D   Toner GC   Seymour JF   Blakey D   Haylock D   Simmons P   Wolf M   Januszewicz EH   Westerman D   Richardson G   Scarlett J   Briggs P  

Cytotherapy, Vol. 4, Iss. 2, 2002-03 ,pp. : 147-155

Ashgate Publishing Ltd

Access to resources Recommend Favorite

A comparison of CFU-GM, BFU-E and endothelial progenitor cells using ex vivo expansion of selected cord blood CD133+ and CD34+ cells

By Lu X.   Baudouin SV   Gillespie JI   Anderson JJ   Dickinson AM  

Cytotherapy, Vol. 9, Iss. 3, 2007-01 ,pp. : 292-300

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Use of selected CD34⁺ cells in the treatment of relapsed/progressive HD: experiences from a single center

By Lakota J   Ballová V   Drgoňa L'   Ďurkovič P   Vranovský A  

Cytotherapy, Vol. 4, Iss. 2, 2002-03 ,pp. : 177-180

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Predictors of high yield and purify of CD34⁺ cell-selected PBPC, collected from patients with multipe myeloma

By Webb I J   Scholssman R L   Jiroutek M   Doss D   Cohen C A   Freeman A   Schott D M   Anderson K C  

Cytotherapy, Vol. 1, Iss. 3, 1999-01 ,pp. : 175-182

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Autologous transplantation: the viable transplanted CD34 + cell dose measured post-thaw does not predict engraftment kinetics better than the total CD34 + cell dose measured pre-freeze in patients that receive more than 2×10 6 CD34 + cells/kg

By Abrahamsen JF   Wentzel-larsen T   Bruserud Ø  

Cytotherapy, Vol. 6, Iss. 4, 2004-08 ,pp. : 356-362

Ashgate Publishing Ltd

Access to resources Recommend Favorite